Immunome to Participate in the Leerink Partners Global Biopharma Conference
07 Marzo 2024 - 2:00PM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused
on developing first-in-class and best-in-class targeted cancer
therapies, today announced that Clay Siegall, Ph.D., President and
CEO of Immunome, will present at the Leerink Partners 2024 Global
Biopharma Conference on Tuesday, March 12, 2024 at 4:20 p.m.
ET.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company’s
website at www.immunome.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 30
days.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including radioligand therapies, ADCs, small molecules and
immunotherapies. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240307194061/en/
Investor Contact Max Rosett Interim Chief Financial
Officer investors@immunome.com
Grafico Azioni Immunome (NASDAQ:IMNM)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Immunome (NASDAQ:IMNM)
Storico
Da Set 2023 a Set 2024